Shuttling of specific proteins out of the nucleus is essential for the regulation of the cell cycle
and proliferation of both normal and malignant tissues. Dysregulation of this fundamental …

The intracellular location of a protein is crucial to its normal functioning in a cell. Cancer cells
utilize the normal processes of nuclear-cytoplasmic transport through the nuclear pore …

The nuclear export protein XPO1 is overexpressed in cancer, leading to the cytoplasmic
mislocalization of multiple tumor suppressor proteins. Existing XPO1-targeting agents lack …

Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy
of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1) …

The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic
target in human multiple myeloma (MM). Here we showed that chromosome region …

Inactivation of p53 functions is an almost universal feature of human cancer cells. This has
spurred a tremendous effort to develop p53 based cancer therapies. Gene therapy using …

This study explored the anti‐leukaemic efficacy of novel irreversible inhibitors of the major
nuclear export receptor, chromosome region maintenance 1 (CRM 1, also termed XPO 1) …

Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1
protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors …

The nuclear transport proteins, importins and exportins (karyopherin-β proteins), may play
an important role in cancer by transporting key mediators of oncogenesis across the nuclear …

Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …